

1 **Title:**

2 **Intraluminal neutrophils limit epithelium damage by reducing pathogen assault on intestinal**
3 **epithelial cells during *Salmonella* gut infection**

4 **Authors:**

5 Ersin Gül¹, Stefan A. Fattinger^{1,2}, Bidong D. Nguyen¹, Annika Hausmann¹, Markus Furter¹, Manja
6 Barthel¹, Mikael E. Sellin², Wolf-Dietrich Hardt^{1*}

7
8 **Affiliations:**

9 ¹Institute of Microbiology, Department of Biology, ETH Zurich, Zurich, Switzerland

10 ²Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala
11 University, Uppsala, Sweden

12
13 ***Correspondence:**

14 hardt@micro.biol.ethz.ch

15 **Summary:**

16 Recruitment of neutrophils into the gut epithelium is a cardinal feature of intestinal inflammation in
17 response to enteric infections. Previous work using the model pathogen *Salmonella* Typhimurium (*S.*
18 *Tm*) established that invasion of intestinal epithelial cells by *S.Tm* leads to recruitment of neutrophils
19 into the gut lumen, where they can reduce pathogen loads transiently. Notably, a fraction of the pathogen
20 population can survive this defense, re-grow to high density, and continue triggering enteropathy.
21 However, the functions of intraluminal neutrophils in the defense against enteric pathogens and their
22 effects on preventing or aggravating epithelial damage are still not fully understood. Here, we address
23 this question via neutrophil depletion in different mouse models of *Salmonella* colitis, which differ in
24 their degree of enteropathy. In an antibiotic pre-treated mouse model, neutrophil depletion by an anti-
25 Ly6G antibody exacerbated epithelial damage. This could be linked to compromised neutrophil-
26 mediated elimination and reduced physical blocking of the gut-luminal *S.Tm* population such that the
27 pathogen density remained high near the epithelial surface throughout the infection. The removal of
28 luminal *S. Tm* by gentamicin, an antibiotic restricted to the gut lumen, reversed the effect of neutrophil
29 depletion on epithelial cell loss. Strikingly, when using germ-free mice and an *S. Tm ssaV* mutant
30 capable of epithelium invasion, but attenuated for survival and growth within host tissues, neutrophil
31 depletion caused exacerbated immune activation of the gut mucosa and a complete destruction of the
32 epithelial barrier. Together, our data indicate that intraluminal neutrophils are central for maintaining
33 epithelial barrier integrity during acute *Salmonella*-induced gut inflammation, by limiting the sustained
34 pathogen assault on the epithelium in a critical window of the infection.

35

36 **Highlights:**

- 37 ○ After the first wave of mucosal invasion (day 1 p.i.), *S. Tm* maintains the assault from the lumen,
38 triggering the continued expulsion of epithelial cells in antibiotic pre-treated mice.
- 39 ○ Neutrophil recruitment into the gut lumen is essential to limit this continued *Salmonella* attack
40 on the epithelium.
- 41 ○ In antibiotic pre-treated SPF mice, neutrophil depletion exacerbates *S. Tm* invasion, causing
42 excessive epithelial cell loss, which compromises epithelial barrier integrity at later time points
43 (day 2-3 p.i.).
- 44 ○ In germ-free mice, neutrophil depletion exacerbates epithelial responses and epithelial barrier
45 destruction even more strongly than in streptomycin pre-treated SPF mice.
- 46 ○ Gentamicin treatment and *ssaV* mutant infections indicate that neutrophils prevent epithelial
47 damage by eliminating and physically blocking gut-luminal pathogens.

48 **Introduction:**

49 Polymorphonuclear leukocytes (PMN), also called neutrophils, are the most abundant immune cell type
50 in circulation and considered as an early line of defense against many infections, including those caused
51 by enteropathogenic bacteria. Neutrophil recruitment into and across the gut epithelium is a hallmark of
52 infectious (e.g., pathogen-induced) and non-infectious (e.g., inflammatory bowel disease) colitis [1-6].
53 They provide a powerful defense during enteric infections using a myriad of effector mechanisms (i.e.,
54 reactive oxygen/nitrate species (ROS/RNS), antimicrobial peptides (MPO/NE), and neutrophil
55 extracellular traps (NETs) [7, 8]. While being indispensable in the defense against microbes, neutrophils
56 are also often associated with tissue damage during gut inflammation [5]. Therefore, the degree of
57 protective versus tissue damaging effects of neutrophils is highly context dependent and is not fully
58 understood for all natural infections and infection models traditionally used in the field.

59 Intestinal inflammation caused by enteric pathogens such as Non-typhoidal *Salmonella enterica*
60 serovars (NTS), including serovar Typhimurium (*S.Tm*) has been extensively studied in recent years.
61 Murine models of *S.Tm* gut inflammation such as the Streptomycin pre-treatment model provide an
62 excellent basis to study the stages of gut inflammation during *Salmonella* infection [9, 10]. To elicit
63 disease in streptomycin pre-treated mice, *S.Tm* invades intestinal epithelial cells using its type-three
64 secretion systems (TTSS)-1 and -2 [2]. Invasion of the epithelial cells results in activation of the NLRC4
65 inflammasome. This results in two major outcomes: i) expulsion of infected epithelial cells into the gut
66 lumen and ii) recruitment of innate immune cells including neutrophils via secretion of IL-18 and other
67 immune mediators (Müller et al., 2016; Sellin et al., 2014). Studies in this model suggest that neutrophils
68 may have stage-specific functions during the acute infection. In the first 18h after an oral dose of *S.Tm*,
69 neutrophils appear not to be involved in defense against *Salmonella* [11]. However, follow-up research
70 using the same model showed that Gr-1+ cells (neutrophils and monocytes) impose a strong bottleneck,
71 reducing the gut luminal *S.Tm* population to as little as 15'000 *S.Tm* cells by 48-72h p.i. [12]).
72 Interestingly, the pathogen population can grow back by 96h p.i. (to approx. 10⁹ CFU / g feces).
73 However, it remains unclear if these high pathogen densities in the gut lumen may represent an important
74 continued driver of enteropathy at that stage of the infection as well. Similarly, due to their stage-specific
75 effects, it remains unclear whether the recruitment of neutrophils is beneficial or rather a detriment for
76 gut mucosal integrity during acute *Salmonella* infection.

77 Infected epithelial cells are expelled during enteric diseases to prevent the subsequent
78 transmigration of the pathogens into the underlying tissue (lamina propria; LP) and the systemic organs
79 [13-17]. Moreover, the expulsion may limit the amounts of inflammasome-dependent cytokines like IL-
80 18 which are released into the lamina propria. The resulting immune responses lead to temporary
81 shortening of the intestinal crypts and require the rapid division of crypt stem cells to retain barrier
82 integrity (crypt hyperplasia; [10, 15, 18]). A failure to replace the expelled epithelial cells, as reported
83 in germ-free mice infected with wild type *S. Tm* [18], can lead to shortened crypt structures and can be

84 detrimental to epithelial barrier integrity. Similarly, excessive assault on epithelial cells and increased
85 pathogen tissue loads due to the lack of one or more of the mucosal defenses can also drive pathological
86 cell loss and destruction of the epithelium. This was shown in the examples of NAIP/NLRC4 or
87 GSDMD (downstream of NLRC4 inflammasome; executor of pyroptotic cell death [19]) deficiency,
88 where failure to initiate timely epithelial immune responses resulted in increased pathogen loads and
89 disruption of the epithelium at later stages of the infection [20, 21]. These reports highlight the
90 importance of a balanced and timely mucosal immune response to maintain epithelium integrity during
91 enteric infections. However, as wild type *S. Tm* colonizes the gut lumen, the gut epithelium and the
92 lamina propria, it remained unclear which of these pathogen populations would be targeted by the
93 neutrophil defense and how this affects the epithelial barrier. We hypothesized that neutrophils might
94 provide an additional layer of defense in the gut lumen and alleviating the burden on the gut epithelium
95 during severe stages of acute *Salmonella* infection.

96 Here we used a comprehensive approach to assess the function of intraluminal neutrophils
97 during *Salmonella*-induced gut inflammation. Utilization of mouse models with varying severity of
98 *S.Tm*-induced colitis allowed us to highlight the stages of gut inflammation where neutrophils exert a
99 crucial epithelium-protective function in the infected gut.

100 **Results:**

101 **Neutrophils slow down the progression of cecal tissue infection by day 3 of *S.Tm* infection**

102 We previously showed that Gr-1+ cells (neutrophils and monocytes) contribute to the control of
103 the gut-luminal pathogen population in the streptomycin mouse model for acute *Salmonella* gut
104 infection. This defence eliminates $\approx 99.999\%$ of the gut luminal *S.Tm* population by day 2 p.i. [12].
105 Interestingly, the luminal pathogen population can grow back up to $\approx 10^9$ CFU / g stool by days 3-4 p.i.
106 However, it remained unclear whether the tissue-lodged or the re-growing luminal pathogen population
107 contribute to the enteropathy at this “mature” stage of the infection. Similarly, the role of intraluminal
108 vs tissue-lodged neutrophils during this stage of *Salmonella* gut infection was still an enigma. Here, we
109 addressed these topics and specifically focused on the consequences of neutrophil depletion on the
110 epithelial barrier, which has previously been shown to respond to *S.Tm* onslaught by a sensitive
111 epithelial cell expulsion response [13, 15, 21, 22]. To explore this, we orally infected streptomycin
112 pretreated C57BL/6 mice with 5×10^7 CFU of wild-type *S.Tm* (SL1344) for 3 days. To detect possible
113 bottlenecks on the luminal pathogen population, we included seven wild-type isogenic tagged *S. Tm*
114 strains in the inoculum (WITS; [23, 24]) at a ratio of 1:1000 (tagged: untagged). This ratio of tagged
115 versus untagged wild-type strains will result in the random loss of abundance in one or more of the
116 tagged strains if the gut-luminal *S.Tm* population undergoes a transient bottleneck. Importantly, the
117 resulting unequal tag-distribution will be maintained within the luminal *S.Tm* population, even after the
118 population has re-grown to carrying capacity at day 3 p.i.. Therefore, qPCR analysis of the tag
119 abundances allows us to quantitatively assess gut luminal bottlenecks in the streptomycin pre-treatment

120 mouse model [12]. To assess the role of neutrophils specifically, we treated mice with a neutrophil-
121 depleting antibody directed against Ly6G (α -Ly6G; cl. 1A8; via intraperitoneal injection (I.P.); see
122 details in **Materials & Methods**). This method reduces the number of neutrophils recruited to the gut
123 tissue during *Salmonella* infection (**Fig. 1A**; [11]). In control experiments, we infected the mice with
124 the same protocol but treated them with PBS only. In line with our previous studies, neutrophil depletion
125 did not change the pathogen densities in the feces or systemic nor did it cause a bottleneck on the gut
126 luminal *S.Tm* population (both groups; evenness score: ~ 1) during the first stage of the acute disease
127 (first 2 days p.i.; **Fig. S1A-D**; [12]). At a later stage (day 3 p.i.), on the contrary, 24 out of 77 WITS
128 were lost in the control (evenness score: ~ 0.46 ; **Fig. 1B-C**), while neutrophil-depleted mice retained a
129 much higher fraction of all tags (only 3 out of 49 WITS were lost with an evenness score: ~ 0.92 ; **Fig.**
130 **1B-C**), confirming the role of neutrophils in this previously observed bottleneck effect. This was similar
131 to our previous observations with the Gr-1-based depletion (anti-Gr-1 antibody; both monocytes and
132 neutrophils depleted). Furthermore, the luminal pathogen densities in the cecal content were
133 significantly higher in mice with neutrophil depletion compared to the control mice both at day 2 and at
134 3 p.i. (**Fig. S1E**) as we also showed before [12]. In conclusion, these data reproduced the role of
135 neutrophils in inflicting a transient bottleneck on the gut luminal *S. Tm* population and provided us with
136 materials to assess the effects of the neutrophil depletion on the enteropathy, which had not been
137 assessed in the earlier work.

138 To assess the degree of enteropathy at later stages, we focused on the cecal tissue (main site of
139 invasion in streptomycin pretreated model [10]). Strikingly, fluorescence microscopy of cecal tissue at
140 day 2 p.i. revealed massive epithelial shedding in mice with neutrophil depletion, while the control mice
141 showed only a few epithelial cell expulsion events. (**Fig. 1D-E**). The mice with neutrophil depletion had
142 on average 5-fold more expelled cells in the cecum lumen and showed disrupted crypt structure, whereas
143 the control mice featured the typical infection-associated crypt hyperplasia. (**Fig. 1D-E**). Of note, at this
144 stage, epithelial cells often dislodged from the mucosa in the form of large cell aggregates, which is
145 different from the typical NAIP/NLRC4-driven epithelial cell expulsion that we and others described
146 before, where single infected cells are selectively extruded by their neighbours [13, 21, 22]. However,
147 the underlying causes remained unclear.

148 We reasoned that in the absence of neutrophils, epithelial cells might be subject to more *S.Tm*
149 invasion events as the gut luminal pathogen loads remained higher than in the non-depleted controls
150 during the bottleneck-phase of the infection (i.e. day 2 p.i.). This might result in higher net pathogen
151 invasion into the gut tissue. To test this, we quantified the pathogen loads in the cecal tissue using the
152 gentamicin protection assay. Indeed, the number of *S.Tm* per cecal tissue was elevated in neutrophil-
153 depleted mice in comparison to the control mice at day 3 p.i. (**Fig. 1F**). The elevated tissue invasion
154 frequency was also reflected in spleen and liver (**Fig. S1F**). However, pathogen loads in the mLN did
155 not differ significantly between the depleted mice and the controls (**Fig. S1F**). The reasons for this
156 remain unclear, but this observation could be linked to the balance between pathogen migration into the

157 mLN, the pathogen growth in that organ and the antimicrobial defense mounted dynamically to control
158 pathogen growth at that site [23]. Taken together, these observations suggest that in the absence of
159 neutrophil defense, the gut mucosa experiences higher *S.Tm* loads at ~2-3 days of infection, coupled to
160 excessive and uncontrolled shedding of intestinal epithelial cells into the lumen.

161

162 **Neutrophils provide a physical barrier against *S. Tm* invading from the gut lumen**

163 It was shown that following an acute *Toxoplasma gondii* gastrointestinal infection of mice,
164 neutrophils can form intraluminal casts that contain commensal outgrowth and prevent spread of
165 pathobionts to the systemic organs [25]. Besides, neutrophils have been shown to interact with luminal
166 *S.Tm* closely during the early stages (at 20h p.i.) of our streptomycin mouse model [1]. Therefore, we
167 speculated that neutrophils might not only be killing luminal pathogens, but also may form a physical
168 barrier to reduce *S.Tm* access to the epithelial surface, thereby restricting further pathogen invasion
169 events. Fluorescence microscopy of cecal tissue at day 1 and 3 p.i. revealed that intraluminal neutrophils
170 and luminal *S.Tm* were in close contact in streptomycin pretreated mice (**Fig. 2A**). At day 1 p.i.,
171 neutrophils were present in the gut lumen in aggregates of various sizes (ca. 2 cells to 50 cells). We
172 asked whether there was a correlation between the size of the neutrophil aggregates in the lumen and
173 the number of *S. Tm* cells interacting with the epithelium at this time point (**Fig. 2B**). To quantify this,
174 we calculated the median number of neutrophils per 63-X field of view and compared the number of
175 *S.Tm* cells interacting with the epithelium in two scenarios, that is in fields of view with >15 neutrophils
176 vs fields of view with ≤ 15 neutrophils. Strikingly, the number of *S.Tm* cells in close association with
177 the epithelium was significantly higher in the scenario where there were only a few (≤ 15) neutrophils in
178 the area in comparison to the scenario with >15 neutrophils (**Fig. 2B**). Of further note, we observed that
179 the number of neutrophils in the gut lumen was significantly higher at day 3 p.i. compared to day 1 p.i.
180 (**Fig. 2C**). At day 3 p.i., neutrophils assembled into dense structures in front of the epithelium
181 reminiscent of the intraluminal casts reported in other contexts [25]. In accordance with this, the average
182 numbers of epithelium-associated pathogen cells were significantly lower at day 3 p.i. compared to day
183 1 p.i. (**Fig. 2D**). Altogether, our findings suggest that in response to *S.Tm* infection neutrophils are
184 recruited to the gut lumen where they both kill *S.Tm*, resulting in a population bottleneck, and at the
185 same time generate a physical barrier against *Salmonella* cells building up from day 1 p.i. onwards in
186 the streptomycin pre-treated mouse model.

187 **Neutrophils release extracellular traps (NETs) into the gut lumen in response to acute** 188 ***Salmonella* infection**

189 Next, we investigated the nature of the neutrophil barrier(s) against pathogen attack. Neutrophils
190 are equipped with an arsenal of anti-microbial effector mechanisms including phagocytosis, release of
191 reactive oxygen/ nitrogen species (ROS/RNS), granules filled with antimicrobial agents, and can in
192 addition release neutrophil extracellular traps (NETs; [7, 8, 26]). NETs are networks of extracellular

193 host-DNA decorated with antimicrobial peptides. They are released in response to several stimuli and
194 can kill or immobilize the pathogens in the extracellular space [27]. We speculated that the release of
195 NETs into the gut lumen could provide one mechanism by which neutrophils limit further *S.Tm* invasion
196 into the cecum epithelium. Since their discovery two decades ago [26] as a powerful and unorthodox
197 immune defense mechanism, NETs have been implicated not only in the defense against many
198 extracellular pathogens [27]), but also in tissue damage and autoinflammatory diseases [5, 28, 29]. We
199 reasoned that NETs-entrapped *S.Tm* cells might not only be immobilized, but might also be efficiently
200 removed with the fecal flow. NETs are generated during a programmed cell death known as ‘NETosis’,
201 which is initiated by peptidyl arginine deiminase-4 (PAD4, aka Padi4), promoting the formation of
202 citrullinated histone 3 (cit-His3). A previous study showed that PAD4 is necessary for an efficient
203 neutrophil response to the enteric pathogen *Citrobacter rodentium* [30]. Therefore, cit-His3 can be used
204 as a marker for NETs. Our microscopy analysis of intraluminal neutrophil aggregates at day 3 p.i. indeed
205 revealed that parts of these aggregates contained DNA with citrullinated histones (**Fig. 3A**).
206 Interestingly, these cit-His3+ regions showed an overlap with regions where *S.Tm* cells were densely
207 localized in the lumen. These results suggest that intraluminal neutrophils can undergo NETosis during
208 acute *Salmonella* infection to kill/immobilize the pathogen and reduce further attacks onto the
209 epithelium.

210 Next, we set out to test if NETosis could be blocked in the gut lumen of our mouse model. For
211 this purpose, we used the PAD4 inhibitor, GSK484, shown to effectively reduce the formation of NETs
212 by mouse and human neutrophils [31, 32]. Here we asked if PAD4 inhibition could prevent the observed
213 bottleneck of the luminal *S. Tm* population (**Fig. 1B-C**). We infected mice as described in Fig. 1 using
214 a mixture of untagged and tagged *S. Tm* (1:1000), treated them with the PAD4 inhibitor GSK484 (**Fig.**
215 **3B**; see details in **Materials & Methods**), and compared the results to the control mice from **Fig. 1**.
216 Inhibition of PAD4 did, however, only result in a weak non- significant trend in the size of the gut lumen
217 bottleneck (**Fig. 3B-D**; evenness score: ~0.67 vs 0.46, p=0.44). Moreover, the pathogen densities in the
218 feces and systemic organs did not change (**Fig. S2A-B**). Microscopy images of the infected cecum
219 revealed that neutrophil aggregates in the gut lumen still contained detectable cit-His3+ DNA also in
220 mice treated with the inhibitor (**Fig. 3A**). It should be noted that strategies to pharmacologically prevent
221 NETosis are still under investigation [33], and it seems clear that our approach incompletely prevented
222 neutrophil NETosis in the gut lumen of our *in vivo*-infection model. Nevertheless, our results show that
223 intraluminal neutrophils are closely interacting with *Salmonella* during the acute infection, and that these
224 neutrophils are positive for the NETosis marker cit-His3. This suggests that the release of NETs into the
225 gut lumen occurs and might contribute to defense during *S.Tm* infection.

226 **Intraluminal neutrophils limit continuous insults to the epithelium and prevent massive** 227 **epithelial cell loss**

228 Our approaches so far suggested a correlation between neutrophil depletion and exacerbated
229 epithelium response to the insult. However, they remained insufficient to establish that the protection of

230 the epithelial barrier is attributable to intraluminal neutrophils. This can partly be explained by the
231 limitations of our experimental infection model. Wild-type (wt) *S. Tm* utilizes TTSS-1 and -2 (encoded
232 on *Salmonella* Pathogenicity Islands (SPI)-1 and -2, respectively) to trigger gut disease [2]. In our mouse
233 model, SPI-2 enables long-term survival of the pathogen at systemic sites and therefore causes a typhoid-
234 like disease at later stages (which becomes very prominent after days 3-4 p.i.). At this stage of infection,
235 other arms of the innate immune system, including neutrophils, are active in the tissue underlying the
236 epithelial layer (e.g., the lamina propria and submucosa) [2]. Therefore, the dramatic epithelial cell
237 shedding we observed in neutrophil-depleted mice could be related to diminished defenses and
238 uncontrolled pathogen growth in deeper tissues. In this case, neutrophil activity in the gut tissue might
239 be more critical for preventing epithelial damage than neutrophils in the gut lumen. To specifically study
240 the consequences of lack of intraluminal neutrophils on epithelial responses to *S. Tm* at mature stages of
241 infection, we infected antibiotic pretreated mice with a SPI-2 mutant (*S. Tm ssaV*; *S. Tm^{ssaV}*). This mutant
242 strain is still able to trigger SPI-1 -dependent gut inflammation and the enteropathy is about as
243 pronounced as for wt *S. Tm* infections, at least during the first 2 days p.i. [2]. However, in contrast to
244 wt *S. Tm*, the *S. Tm^{ssaV}* infection does not progress into a typhoid like disease at later stages [2]. With this
245 new model, we were able to minimize a possible contribution to epithelial cell expulsion or disruptive
246 shedding by pathogen cells residing in deeper tissues. In contrast to our previous model (Fig. 1A), we
247 pre-treated C57BL/6 mice with ampicillin, instead of streptomycin, which ensures more robust infection
248 kinetics in *S. Tm^{ssaV}* infections (unpublished data and [34]). The mice were infected with 5×10^7 CFU of
249 *S. Tm^{ssaV}* for 3 days (experimental scheme; **Fig. 4A**).

250 To probe the significance of intraluminal neutrophils, we compared the effects of neutrophil
251 depletion to a scenario where we removed the luminal pathogen population after day 1 p.i.. The latter
252 was achieved by supplementing the drinking water with gentamicin, an antibiotic which acts locally in
253 the gut lumen but does not cross the epithelium (experimental scheme; **Fig. 4A**). We reasoned that if the
254 exacerbated epithelial response (observed in **Fig. 1D-E**) is caused by continuous high-level pathogen
255 invasion from the luminal side, the gentamicin treatment should alleviate this outcome. First, we
256 validated that our approach specifically removed the luminal pathogen population, while leaving tissue-
257 lodged pathogen populations intact. At day 3 p.i., *S. Tm^{ssaV}* was undetectable in the cecal content in all
258 groups undergoing gentamicin treatment while the pathogen densities stayed high in feces and cecal
259 content throughout the experiment in groups without gentamicin (**Fig. 4B and S3A**). On the other hand,
260 removal of the luminal pathogen population by gentamicin did not affect the pathogen loads in the cecal
261 tissue and the systemic organs at day 3 p.i. in none of the groups infected with *S. Tm^{ssaV}* (**Fig. 4C and**
262 **S3B**, open symbols). This provided an ideal set-up to test the role of intraluminal neutrophils. Second,
263 we assessed if the absence of the luminal pathogen population influenced the enteric disease kinetics.
264 Strikingly, concentrations of Lipocalin-2 (a general marker for gut inflammation) were significantly
265 reduced at day 3 p.i. in the groups treated with gentamicin in the drinking water (both control and
266 neutrophil depletion with gentamicin treatment; **Fig. 4D**). This suggested that the pathogen population

267 in the gut lumen significantly contributes to the maintenance of gut inflammation. Finally, we explored
268 the effect of neutrophil depletion on epithelial integrity. To this end, we compared the number of
269 expelled epithelial cells in control vs neutrophil depleted mice in the absence or presence of gentamicin
270 treatment. In the group without gentamicin treatment, neutrophil depletion caused a significant elevation
271 of expelled epithelial cells compared to the PBS control, as we observed in Fig. 1D (**Fig. 4E-F**).
272 Similarly, the epithelial cells again appeared to dislodge from the mucosa in an uncontrolled manner
273 and in big aggregates in neutrophil-depleted animals (**Fig. 4E**). In stark contrast, neutrophil depletion
274 did not lead to an elevated frequency of epithelial cell expulsion in the group receiving gentamicin
275 treatment (**Fig. 4E-F**). In fact, the gentamicin treatment reduced the numbers of expelled epithelial cells
276 in the lumen down to baseline at 3 days p.i. (compare open symbols to black filled symbols in **Fig. 4F**).
277 This effect was observed in mice both with and without neutrophil depletion. Upon gentamicin
278 treatment, the epithelium ultrastructure also recovered, as judged by clearly defined and organized crypt
279 structures. These findings reveal that epithelial invasion events from the lumen at mature stages of
280 *S.Tm^{ssaV}* infection continue to fuel epithelial cell expulsion, and that intraluminal neutrophils provide a
281 crucial barrier to reduce the frequency of these events so that epithelial barrier integrity can be retained.

282 **The lack of intraluminal neutrophil defense is detrimental for the epithelium in mice lacking a** 283 **resident gut microbiota**

284 Previous studies highlighted microbiota mediated colonization resistance, mucus secretion by
285 goblet cells, antimicrobial peptides secretion, epithelial NAIP/NLRC4 inflammasome, and neutrophil
286 infiltration into the gut lumen as potentially complementary factors protecting the epithelium from
287 pathogen attack. How these various protective systems are integrated with each other remains poorly
288 understood, but it appears conceivable that defects in any of them will result in a heavier reliance on the
289 others, e.g. a more prominent dependence on the luminal neutrophil defense predicted in animals lacking
290 another protection factor. One good example of such a scenario would be the absence of resident
291 microbiota, which has been shown to exacerbate *S.Tm*-induced colitis in mice [18]

292 To test this hypothesis, we infected germ-free mice with 5×10^7 CFU of *S. Tm^{ssaV}* and compared
293 neutrophil-depleted mice to control mice (**Fig. 5A**). Since germ-free mice lack resident microbiota, they
294 are more susceptible to *Salmonella* infection (i.e., one of the defense layers is already missing;
295 colonization resistance by the microbiota [35]). Importantly, the epithelial regeneration which is critical
296 for maintaining epithelial integrity during an acute *S.Tm* infection is also delayed in germ free mice
297 [18]. These features allowed us to scrutinize the role of intraluminal neutrophils even more readily than
298 in antibiotic pretreated mice associated with a conventional microbiota. In germ-free mice, *S. Tm^{ssaV}*
299 colonized the gut to the carrying capacity in both groups and *S.Tm^{ssaV}* was shed at very high numbers
300 until day 3 p.i. ($\sim 10^9$ CFU / g feces; **Fig. 5B**). Moreover, neutrophil depletion did not significantly affect
301 the systemic spread of the pathogen (**Fig. 5C**). However, mRNA expression analysis of cecal tissue
302 revealed a striking difference between depleted and non-depleted mice. Many genes encoding pro-

303 inflammatory cytokines and chemokines associated with the acute *Salmonella* infection were induced
304 to higher levels in the cecum of neutrophil-depleted mice compared to the controls (**Fig. 5D**). This
305 supported our hypothesis that the absence of intraluminal neutrophils leads to an overstimulation of the
306 mucosal immune defense.

307 Next, we asked whether this hyper-activation of the mucosal immune responses is detrimental
308 to the epithelial barrier. To test this, we first analysed the mRNA expression levels of matrix-
309 metalloproteinases (Mmp-8 and -9) associated with inflammation-linked tissue remodelling [36].
310 Indeed, the neutrophil-depleted group showed an elevated mRNA expression of these genes (**Fig. 5D**).
311 Second, we analysed the epithelial barrier integrity and the epithelial regeneration responses in these
312 mice. Strikingly, fluorescence microscopy of cecal tissue at day 2 and 3 p.i. revealed that neutrophil
313 depletion caused a severe loss of epithelial cells and formation of gaps in the barrier (**Fig. 5E-F**). The
314 number of epithelial cells per crypt was also dramatically reduced and organized crypt structures were
315 entirely lost in some mice (**Fig. 5E-F**). To test if this loss of epithelial barrier was associated with a
316 reduced capacity of the epithelial cells to divide, we analysed the fraction of Ki67+ cells. Indeed,
317 actively dividing cells were nearly absent in neutrophil-depleted groups while the active division and
318 crypt hyperplasia was apparent in the control mice infected with *S. Tm*^{ssaV} (**Fig. 5G and S4A**). In control
319 mice, more than 90% of the epithelial cells of a crypt were positive for Ki67. Therefore, the lack of gut
320 microbiota appears to lead to an overwhelming attack on the epithelium during *S. Tm*^{ssaV} infection, which
321 is counteracted by neutrophils. Taken together, these results suggest that in the presence of intraluminal
322 neutrophils, epithelial integrity can be maintained by rapid epithelial proliferation even in germ-free
323 mice, while the depletion of neutrophils is detrimental to the epithelial barrier integrity.

324 **Discussion:**

325 Since neutrophils are central players exerting diverse effector functions during the initial
326 immune response to infections, a full understanding of neutrophil functions in the course of diverse
327 infectious diseases is crucial. In the case of *Salmonella* gut infection, the role of neutrophils has not been
328 fully elucidated. Here we tackled this question and carefully analysed the consequences of neutrophil
329 depletion (with α -Ly6G) during the infection with *S. Tm* in different variants of the mouse model for
330 *Salmonella* gut infection. Our findings revealed that intraluminal neutrophils provide a barrier in front
331 of the epithelium during a critical stage of the infection and that neutrophil function is essential for
332 preventing excessive epithelial cell loss, maintaining epithelial regeneration at a rate that preserves
333 barrier integrity, and thus avoiding epithelium disruption (**Fig. S5A-B**).

334 In this report, we present an epithelium-protective role of neutrophils in three different variants
335 of the mouse infection model for acute Salmonellosis (**Fig. 1,4,5**). The streptomycin pre-treated mouse
336 model is often used to study acute *Salmonella* infection. It employs wt *S. Tm* (i.e., intact SPI-1 and SPI-
337 2) that elicits enteropathy and is further characterized by the successive development of a typhoid-like
338 disease, which can overwhelm Nramp-1-negative mouse strains at later time points (beyond days 5-6

339 p.i.). This parallel systemic infection makes it harder to study the role of immune effector mechanisms
340 that are mounted after the early NAIP/NLRC4-dependent epithelial cell expulsion response [21]. Here,
341 by combining ampicillin pretreatment and germ-free models with a SPI-2 mutant (which fails to grow
342 to high levels at systemic sites), we could resolve the defenses protecting against luminal pathogen
343 insults after day 1 p.i.. Because the mutant pathogen was defective in its ability to grow at systemic sites,
344 we could focus on the luminal events, providing us with vital information regarding the neutrophils`
345 function in the gut lumen. Furthermore, this model revealed that the immune response to the pathogen
346 is highly regulated (i.e., rapid reduction of Lipocalin-2 secretion upon antibiotic treatment; **Fig. 4D-E**).
347 We believe that, although we use a mutant strain in a murine model, these findings may generalize to
348 *Salmonella* gut infections in the wild, which rarely result in detectable systemic infection [37].

349 Our findings highlight the multi-layered nature of the mucosal defence against enteric *S.Tm*
350 infection. In our work, the degree of epithelial damage was different depending on the type of infection
351 model applied. These differences were particularly striking when comparing the ampicillin pre-treated
352 mice in **Fig. 4** with germ-free mice studied in **Fig. 5**. During infection of ampicillin pre-treated
353 conventional mice with *S. Tm*^{ssaV}, neutrophil depletion caused excessive epithelial cell loss, but the
354 crypts stayed intact without any larger gaps in the epithelium. In contrast, neutrophil-depleted germ-free
355 mice developed pronounced epithelial damage and essentially a full collapse of crypt ultrastructure. This
356 highlights the importance of resident microbiota in complementing the here described intraluminal
357 neutrophil defense. Presumably, this is attributable to sub-acute stimulation of innate immune responses
358 by molecular patterns derived from the resident microbiota [38]. Such sub-acute stimulation might
359 enhance the regenerative capacity of the gut epithelium and thereby prevent pronounced epithelium
360 disruption even if neutrophils are depleted. Therefore, the effects of antibiotic-mediated depletion of the
361 gut microbiota should be studied in more detail to gain a deeper understanding of the role of continued
362 sub-acute stimulation of mucosal defences by the microbiota or their loss during antibiotic treatment.
363 Several alternative mouse models which permit *S.Tm* gut infections in the face of a pre-existing
364 microbiota, such as low-complexity microbiota-bearing OligoMM¹² mice or transient diet shift models,
365 have been proposed recently [39, 40]. We hypothesize that studying the host immune responses to
366 *Salmonella* infection in models with milder microbiota perturbation can provide us with important new
367 insights regarding microbiota – innate immune defense integration.

368 Neutrophil extracellular traps (NETs) are proposed as a potent effector mechanism deployed by
369 neutrophils to kill bacteria [26]. In the past two decades, several reports highlighted that NETs (that is
370 host DNA decorated with antimicrobial agents) are not only a potent antimicrobial mechanism, but that
371 NETs can also cause tissue damage and elicit autoimmunity in many diseases [27]. These reports
372 challenged the idea that NETs are a highly specific anti-infective defense mechanism, as there are only
373 few cases where NET release occurs without negative side-effects. Our observations suggest that the
374 intestinal lumen may be a unique site for deploying NETs as a specific anti-infective defense, without

375 risking NET-mediated tissue damage or autoimmunity. Our results show that aggregates of neutrophils
376 in the gut lumen are positive for one of the NETosis markers, citrullinated histone 3. Although our
377 approach to demonstrate a functional role of NETosis in the defense against enteric *S.Tm* infection only
378 showed a weak trend, our results still draw an interesting image: intraluminal neutrophils may release
379 NETs to physically trap and possibly kill enteric pathogens. Due to their accumulation on the luminal
380 surface of the intestinal mucosa, this defence would be directed specifically against motile *S.Tm* cells
381 [41, 42] that are in the process of swimming towards the epithelium. Moreover, it is tempting to
382 speculate that the entrapped *S.Tm* cells could then be transported and excreted with the fecal flow.
383 Further research is required to demonstrate if indeed NETs function as a “death-plus-disposal” trap for
384 *Salmonella*. Nevertheless, our study does substantiate that neutrophils form large intraluminal
385 aggregates that physically and/or biochemically shields the epithelium for sustained pathogen attack.
386 These findings support and extend earlier work on how neutrophils can confine pathobiont expansion
387 by intraluminal casts following a primary infection [25].

388 In summary, we have presented evidence for the protective role of intraluminal neutrophils
389 during key stages of acute *Salmonella* infection in mice, by providing a protective barrier against luminal
390 pathogen attack and hence giving the epithelium time to recover through crypt cell proliferation. Of
391 note, our findings are limited to the murine models described in this study, and further research will be
392 needed to assess if intraluminal neutrophils function in a similar fashion in other relevant scenarios and
393 hosts. Our findings provide a basis for future research to disentangle the molecular mechanism(s) by
394 which neutrophils exert this protective role, and to explore if these observations can be broadly applied
395 across the diversity of enteroinvasive infections.

396 **Acknowledgements:**

397 We would like to thank members of the Hardt lab and Slack Lab for helpful discussions. We
398 acknowledge the staff of the ETH Zürich mouse facility EPIC/RHCI (especially Manuela Graf,
399 Katharina Holzinger, Dennis Mollenhauer, Sven Nowok & Dominik Bacovcin) and the staff of the
400 Microbiology Institute. Valuable comments on the manuscript by Luca Maurer and Erik Bakkeren are
401 gratefully acknowledged. This work has been supported by grants from the Swiss National Science
402 Foundation (310030_192567, NCCR Microbiomes), and the Monique Dornonville de la Cour
403 Foundation to WDH.

404 **Author contributions:**

405 Conceptualization: EG, WDH. Methodology: EG, SAF. Investigation: EG, SAF, BDN, AH,
406 MF, MES, WDH. Technical assistance: AH, MB, MF. Writing - Original Draft: EG. Writing - Review
407 & Editing: EG, MES, WDH. Visualization: EG. Funding acquisition: WDH.

408 **Declaration of interests:**

409 The authors declare no conflicts of interest.




Figure 1




Figure 2










Figure 3


A




C



D



E



F





Figure 4


A

Germ-free infection




B

Germ-free colonization




C

Systemic spread




D


Cecal epithelium immune activation



E



F



G




Figure 5




Figure S1




Figure S2





Figure S3

A

**Control
(PBS)**


**Neutrophil Depletion
(α -Ly6G)**



Day 3 p.i.

Figure S4

A Scenario 1: In the presence of intraluminal neutrophil defense



B Scenario 2: In the absence of proper intraluminal neutrophil defense




Figure S5

410 **Figure captions:**

411 **Fig.1 Consequences of neutrophil depletion with α -Ly6G on luminal pathogen loads and epithelial**
412 **cell expulsion**

413 **A)** Scheme summarizing the experimental setup of Panels **B-F**. Streptomycin pre-treated C57BL/6 mice
414 were infected orally with 5×10^7 CFU of wt *S.Tm* (SL1344) for 3 days. One group (control) treated with
415 the vector (PBS; black symbols) and the second group with α -Ly6G (orange symbols) intraperitoneally
416 (I.P.). **B)** Relative ranks of the tagged *S.Tm* strain abundances in feces at day 3 p.i. **C)** Evenness score
417 at day 3 p.i. **D)** Representative micrographs of cecal tissue sections, stained for epithelial marker EpCam
418 and *Salmonella* LPS. Lu. = Lumen. White arrows point at expelled epithelial cells. Scale bar=50 μ m. **E)**
419 Microscopy-based quantification of IECs per 63x field of view (i.e., cells/high power field; hpf). Each
420 data point is the average of 5 fields of view (FOV) per section. **F)** *S.Tm* pathogen loads in cecal tissue
421 (CFU / g). Lines or Upper ends of the bars indicate the median. Dotted lines indicate the detection limit.
422 **Panels B-C)** Pooled from 2 independent experiments for each group: control (n=11 mice) and neutrophil
423 depletion (n=7 mice). **Panels D-F)** Pooled from 3 independent experiments for each group: control (n=8
424 mice) and neutrophil depletion (n=9 mice). Two-tailed Mann Whitney-U tests were used to compare
425 two groups in each panel. $p \geq 0.05$ not significant (ns), $p < 0.05$ (*), $p < 0.01$ (**).

426

427 **Fig.2 Microscopy analysis of the time course of neutrophil infiltration into the gut lumen (day 1**
428 **& 3 p.i.)**

429 **A)** Representative micrographs of cecal tissue sections from mice infected with *S.Tm*, taken at day 1
430 and 3 p.i., stained for neutrophil marker Ly6B.2 and *Salmonella* LPS. Lu.=Lumen. Ep.=Epithelium.
431 White arrows indicate *S.Tm* associated with the epithelium. Scale bar=50 μ m. **B-D)** Microscopy-based
432 quantification of **B)** *S.Tm* associated with the epithelium at day 1 p.i.. (total 24 FOVs from 6 mice; filled
433 symbols; neutrophils per field ≤ 15 vs empty symbols; neutrophils per field > 15). **C)** neutrophils per 63x
434 field of view (each data point is the average of 5 FOVs per section of the same mouse). **D)** average
435 number of *S.Tm* associated with the epithelium. Upper ends of the bars indicate the median. Dotted lines
436 indicate the detection limit. **Panels C-D)** Pooled from 3 independent experiments for each group: day 1
437 p.i. (n= 6 mice) and day 3 p.i. (n=9 mice). Two-tailed Mann Whitney-U tests were used to compare two
438 groups in each panel. $p \geq 0.05$ not significant (ns), $p < 0.01$ (**), $p < 0.001$ (***)

439

440 **Fig.3 Microscopy analysis of intraluminal NETs at day 3 p.i.**

441 **A)** Representative micrographs of cecal tissue sections from mice infected with *S.Tm*, taken at 3 days
442 p.i., stained for NET marker cit-His3 and *Salmonella* LPS. Lu. = Lumen. Ep. = Epithelium. Yellow
443 arrows indicate *S.Tm* associated with the NET marker cit-His3. White dotted lines indicate the epithelial
444 barrier. Scale bar=50 μ m. **B)** Experimental scheme of **Panels C-D**. Streptomycin pre-treated C57BL/6
445 mice were infected orally with 5×10^7 CFU of wt *S.Tm* for 3 days. One group (control from **Fig. 1B-C**)

446 treated with the vector (PBS; black symbols) and the second group with PAD4 inhibitor (GSK484;
447 purple symbols) intraperitoneally (I.P.). **C)** Relative ranks of the tagged *S. Tm* strain abundances in feces
448 at day 3 p.i.. **D)** Evenness score at day 3 p.i.. Upper ends of the bars indicate the median. **Panels C-D)**
449 Pooled from 2 independent experiments for each group: control (n= 11 mice) and PAD4 inhibition (n=5
450 mice). Two-tailed Mann Whitney-U tests were used to compare two groups in each panel. $p \geq 0.05$ not
451 significant (ns).

452

453 **Fig.4 Investigation of the role of intraluminal neutrophils in a mouse model with reduced systemic** 454 **disease**

455 **A)** Experimental scheme of **Panels B-F)**. Ampicillin pretreated C57BL/6 mice were infected orally with
456 5×10^7 CFU of *S. Tm^{ssaV}* for 3 days. Mice were divided into four groups: 1) Control (I.P. PBS; black
457 filled symbols) without gentamicin, 2) Neutrophil depletion (I.P. α -Ly6G; orange filled symbols)
458 without gentamicin, 3) Control (I.P. PBS; black empty symbols) with gentamicin in drinking water
459 starting from day 1 p.i., and 4) Neutrophil depletion (I.P. α -Ly6G; orange empty symbols) with
460 gentamicin in drinking water starting from day 1 p.i. Total *S. Tm^{ssaV}* pathogen loads **B)** in cecal content,
461 **C)** in the cecal tissue at day 3 p.i. in each group. **D)** Quantification of gut inflammation by Lipocalin-2
462 levels in cecal content. **E)** Representative micrographs of cecal tissue sections, stained for epithelial
463 marker EpCam and *Salmonella* LPS. Lu.=Lumen. EP.=Epithelium. White arrows point at expelled
464 epithelial cells. Scale bar=50 μ m. **F)** Microscopy-based quantification of luminal IECs per 63x field of
465 view (i.e., cells/high power field; hpf). Each data point is the average of 5 fields of view (FOV) per
466 section. Upper ends of the bars indicate the median. **Panels B-F)** Pooled from total 4 independent
467 experiments; at least 2 for each group: Group-1 (n=12 mice), group-2 (n=9 mice), group-3 (n=6 mice),
468 group-4 (n=6 mice). Two-tailed Mann Whitney-U tests were used to compare two indicated groups in
469 each panel. $p \geq 0.05$ not significant (ns), $p < 0.05$ (*), $p < 0.001$ (***)).

470

471 **Fig.5 Consequences of neutrophil depletion on epithelial health during *S. Tm^{ssaV}* infection of germ-** 472 **free mice**

473 **A)** Experimental scheme of **Panels B-G)**. C57BL/6 germ-free mice were infected orally with 5×10^7 CFU
474 of *S. Tm^{ssaV}* for 2 or 3 days (mice were euthanized at either day according to the health status of the
475 neutrophil-depleted mice) . Mice were divided into 2 groups: 1) Control (I.P. PBS; black filled symbols),
476 2) Neutrophil depletion (I.P. α -Ly6G; orange filled symbols). Total *S. Tm^{ssaV}* pathogen loads **B)** in feces,
477 **C)** in mLN and spleen (pooled data from day 2 and 3 p.i.) in each group. **D)** Quantification of mRNA
478 expression levels in the cecal tissue by qRT-PCR, for genes involved in immune response to acute
479 *Salmonella* infection and genes involved in tissue remodelling. Results are represented relative to β -
480 actin mRNA levels. **E)** Representative micrographs of cecal tissue sections, stained for epithelial marker
481 EpCam and *Salmonella* LPS. Lu.=Lumen. EP.=Epithelium. Yellow arrows point at regions with gaps
482 in the epithelial barrier. Scale bar=50 μ m. Microscopy-based quantification of **F)** IECs per 63x field of

483 view and **G**) Ki67+ cells per 63x field of view (i.e., cells/high power field; hpf). Each data point is the
484 average of 5 fields of view (FOV) per section. Upper ends of the bars indicate the median. Data pooled
485 from total 5 independent experiments. Data reported in **Panel B-G** is pooled from mice euthanized at
486 day 2,3 and 4 p.i. as results were indistinguishable after day 2 p.i.. **Panel C**: control (n=5 from day 2
487 and n=4 from day 3), neutrophil depletion (n=5 from day 2 and n=5 from day 3). **Panel D**: control (n=2
488 from day 2, n=4 from day 3, and n=2 from day 4), neutrophil depletion (n=2 from day 2 and n=5 from
489 day 3). **Panel F-G**: control (n=2 from day 2, n=2 from day 3, and n=2 from day 4), neutrophil depletion
490 (n=2 from day 2 and n=3 from day 3). Two-tailed Mann Whitney-U tests were used to compare two
491 indicated groups in each panel. $p \geq 0.05$ not significant (ns), $p < 0.05$ (*), $p < 0.01$ (**).

492

493 **Supplementary Figure captions:**

494 **Fig.S1 Consequences of neutrophil depletion with α -Ly6G on luminal pathogen loads, systemic 495 spread, and epithelial cell expulsion (related to Fig. 1)**

496 **A**) Streptomycin pre-treated C57BL/6 mice were infected orally with 5×10^7 CFU of wild-type *S. Tm*
497 (SL1344) for 3 days. One group (control) was treated with the vector (PBS; black symbols) and the
498 second group with α -Ly6G (orange symbols) intraperitoneally (I.P.). *S.Tm* pathogen loads **A**) in feces
499 until day 3 p.i. (CFU / g) and **B**) in systemic organs at day 2 p.i. (CFU / organ). **C**) Relative ranks of the
500 tagged *S.Tm* strain abundances in feces at day 1 p.i.. **D**) Evenness score at day 1 p.i. **E-F**) *S.Tm* pathogen
501 loads **E**) in the cecal content at day 2 and 3 p.i. (CFU / g) and **F**) in systemic organs (mLN, spleen, and
502 liver) at day 3 p.i. (CFU / organ). Lines or Upper ends of the bars indicate the median. Dotted lines
503 indicate the detection limit. **Panel A**) Pooled from 9 independent experiments for each group: number
504 of mice each day differs as experiments terminated at day 1, 2 or 3 p.i., but n=at least 14 at each day.
505 **Panel B**) Pooled from 4 independent experiments for each group: number of mice for each organ differs,
506 but n=at least 6 for each organ. **Panel C-D**) Pooled from 2 independent experiments for each group:
507 control (n=11 mice) and neutrophil depletion (n=7 mice). **Panel E**) Pooled from at least 3 independent
508 experiments for each group: number of mice for each day differs, but n=at least 8 for each day. **Panel**
509 **F**) Pooled from at least 5 independent experiments for each group: number of mice for each organ
510 differs, but n=at least 14 for each organ. Two-tailed Mann Whitney-U tests were used to compare two
511 groups in each panel. $P \geq 0.05$ not significant (ns), $p < 0.05$ (*), $p < 0.01$ (**), $p > 0.0001$ (****).

512

513 **Fig.S2 Consequences of PAD4 inhibition on luminal pathogen loads and systemic spread (related 514 to Fig. 3)**

515 **A**) Streptomycin pre-treated C57BL/6 mice were infected orally with 5×10^7 CFU of wild-type *S. Tm* for
516 3 days. One group (control from **Fig. S1A and F**) treated with the vector (PBS; black symbols) and the
517 second group with PAD4 inhibitor (GSK484; purple symbols) intraperitoneally (I.P.). *S.Tm* pathogen
518 loads **A**) in feces until day 3 p.i. (CFU / g) and **B**) in systemic organs at day 3 p.i. (CFU (organ). Upper
519 ends of the bars indicate the median. **Panels A-B**) Pooled from 2 independent experiments for each

520 group: control (n= 11 mice) and PAD4 inhibition (n=5 mice). Two-tailed Mann Whitney-U tests were
521 used to compare two groups in each panel. $p \geq 0.05$ not significant (ns).

522

523 **Fig.S3 Analysis of fecal and systemic pathogen loads in a mouse model with reduced systemic**
524 **disease (related to Fig. 4)**

525 Total *S. Tm^{ssaV}* pathogen loads **A**) in feces at day 1-3, **B**) in systemic organs (mLN and spleen) at day 3
526 p.i. in each group. Upper ends of the bars indicate the median. **Panels A-B**) Pooled from total 4
527 independent experiments; at least 2 for each group: Group-1 (n=12 mice), group-2 (n=9 mice), group-3
528 (n=6 mice), group-4 (n=6 mice). Two-tailed Mann Whitney-U tests were used to compare two indicated
529 groups in each panel. $p \geq 0.05$ not significant (ns), $p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$ (***)).

530

531 **Fig.S4 Microscopy analysis of cecal tissue in terms of its regeneration capacity (related to Fig. 5)**

532 **A**) Representative micrographs of cecal tissue sections, stained for epithelial marker EpCam and cell
533 division marker Ki67. LPS. Lu.=Lumen. EP.=Epithelium. White arrows point at regions with gaps in
534 the epithelial barrier. Scale bar=50 μ m.

535

536 **Fig.S5 Proposed working model explaining the sequence of infection events in the presence and**
537 **absence of intraluminal neutrophils**

538 **A**) Presence of intraluminal neutrophil defense. Stage 1: *Salmonella* invasion of the epithelium is sensed
539 by the NAIP/NLRC4 inflammasome in epithelial cells, resulting the expulsion of infected cells into the
540 gut lumen. This leads to shortening of the crypts. At the same time, inflammasome signalling promotes
541 recruitment of immune cells, including neutrophils, into the lamina propria. Stage 2: Neutrophils swarm
542 into the gut lumen where they attack the invading pathogen cells and form aggregates consisting of
543 neutrophils, NETs, and *Salmonella*. Stage 3: This barrier formed by neutrophils block further *Salmonella*
544 attacks on the epithelium temporarily, which allows epithelial cells enough time to divide and re-
545 establish the barrier. **B**) Absence of intraluminal neutrophil defense. Stage 1: *Salmonella* invasion of the
546 epithelium is sensed by the NAIP/NLRC4 inflammasome in epithelial cells, resulting the expulsion of
547 infected cells into the gut lumen. This leads to shortening of the crypts. No neutrophils are recruited.
548 Stage 2: This leaves the epithelium exposed to further *Salmonella* attacks as the luminal population is
549 not faced with a neutrophil counterattack. As a result, the pathogen cells continue to assault the
550 epithelium. Epithelial cells continue to expel in response to these attacks, eventually leading to
551 uncontrolled epithelial cell loss. Stage 3: Massive and continuous shedding result in extremely short
552 crypts and gap formation. The epithelial barrier is breached. Underlying tissue is in direct contact with
553 the gut luminal content.

554

555

556 **Materials and Methods:**

557 **Bacterial strains used in this study**

558 In all experiments, *Salmonella* Typhimurium SL1344 (*S.Tm*;SB300; SmR) or the indicated *ssaV* mutant
559 version (*S.Tm*^{*ssaV*}; M2730; AmpR) were used. [43, 44]. WITS-tags were introduced into *S. Tm* and into
560 by P22 phage transduction and subsequent selection on kanamycin. The presence of the correct WITS-
561 tag was confirmed by PCR using tag-specific primers [12, 45]. For *in vivo* mouse infections, bacteria
562 were grown in lysogeny broth (LB) media containing the appropriate antibiotics (50 µg/ml streptomycin
563 (AppliChem); 15 µg/ml chloramphenicol (AppliChem); 50 µg/ml kanamycin (AppliChem); 100 µg/ml
564 ampicillin (AppliChem)) at 37°C for 12h and sub-cultured in 1:20 LB without antibiotics for 4h. Cells
565 were washed and re-suspended in cold PBS (BioConcept).

566

567 **Mouse infections**

568 C57BL/6 mice with different microbiota complexity (germ-free and specific pathogen free
569 (SPF)) were kept in individually ventilated cages of the ETH Zürich mouse facility (EPIC and RCHCI).
570 Infection experiments in antibiotic pre-treated mice were done according to the previously-described
571 Streptomycin mouse model for *S.Tm* oral infection [10]. Shortly, the mice were pre-treated with 25mg
572 of streptomycin by oral gavage 24h prior to infection and infected on day 0 by oral gavage with an
573 inoculum of 5x10⁷ CFU *S.Tm*. Infections in **Fig. 4** followed the same protocol but a pretreatment instead
574 with 20mg of ampicillin and *S.Tm*^{*ssaV*} oral infection. Germ-free mice infections were done similarly but
575 without any pretreatment. Experiments were performed with 8–12-week-old male or female mice. The
576 sample-size was not pre-determined, and mice were randomly assigned to groups. All animal
577 experiments were approved by the Kantonales Veterinäramt Zürich (licences 193/2016 and 158/2019).

578 Mice were monitored daily, and organs were harvest at the indicted time points. Feces were
579 collected at the indicated time points and where necessary, cecal tissue and mLN were harvested at the
580 end of the infection. For cecal tissue plating, the gentamicin protection assay was used in which the
581 tissue is treated with gentamicin to clear extracellular bacteria. Cecal tissue was cut longitudinally,
582 washed rapidly in PBS (3x), incubated for 45-75min in PBS/400µg/ml gentamicin Sigma-Aldrich) at
583 RT, and washed extensively (3x 30s) in PBS before plating. For plating, the samples were homogenized
584 with a steel ball in a tissue lyser (Qiagen) for 2 minutes at 25Hz frequency (cecal tissue 3 minutes at
585 30Hz). The homogenized samples were diluted in PBS, plated on MacConkey (Oxoid) plates
586 supplemented with the relevant antibiotic(s), and placed at 37°C overnight. Colonies were counted the
587 next day and represented as to CFU / g content. Normalized competitive index (C.I.) was calculated as
588 the ratio of the wild type over the mutant in the feces and normalized to the initial ratio in the inoculum.

589 For *in vivo* depletion of neutrophils, anti-Ly6G (BioXCell, 1A8) was injected intraperitoneally
590 at each day starting at pretreatment (In **Fig.1** 500µg/mouse, in **Fig. 4 and 5** 250 µg/mouse). For PADK4
591 inhibition experiments, the inhibitor GSK484 (500µg/mouse; in 10% DMSO; Cayman Chemical) was
592 injected intraperitoneal daily starting at pretreatment.

593 **qRT-PCR**

594 Cecal tissue sections were snap-frozen in RNAlater solution (Thermo Fisher Scientific) after extensive
595 washing of the content in PBS and stored in -80°C until further analysis. Total RNA was extracted using
596 RNeasy Mini Kit (Qiagen) according to manufacturer's instructions and converted to cDNAs employing
597 RT² HT First Strand cDNA Kit (Qiagen). qPCR was performed with FastStart Universal SYBR Green
598 Master reagents (Roche) and Ct values were recorded by QuantStudio 7 Flex FStepOne Plus Cycler.
599 Primers were designed using the NCBI primer-designing tool (see **Table 1**) or ordered as validated
600 primers from Qiagen. The mRNA expression levels were plotted as relative gene expression to β-actin
601 (2^{-ΔCt}) and comparisons are specified in the figure caption.

602

603 **Table 1. Primer Sequences used for real time qRT-PCR**

Gene Name		Primer Sequence (5'→3')
β-actin (mouse)	F	AGAGGGAAATCGTGCGTGAC
	R	CAATAGTGATGACCTGGCCGT
Cxcl1 (mouse)	F	CCGCTCGCTTCTCTGTGC
	R	CTCTGGATGTTCTTGAGGTGAATC
Cxcl2 (mouse)	F	CGCCCAGACAGAAGTCATAG
	R	TCCTCCTTTCCAGGTCAGTTA
Il12a(mouse)	F	TGTGGGAGAAGCAGACCCTTA
	R	GGGTGCTGAAGGCGTGAA
Adgre1 (mouse)	F	CTTTGGCTATGGGCTTCCAGTC
	R	GCAAGGAGGACAGAGTTTATCGTG
Il1β (mouse)	F	GCAACTGTTCCCTGAACCTCAACT
	R	ATCTTTTGGGGTCCGTCAACT
Il6 (mouse)	F	CCTCTGGTCTTCTGGAGTACC
	R	ACTCCTTCTGTGACTCCAGC
Il1a (mouse)	F	Qiagen
	R	
Tnfa (mouse)	F	ATGAGCACAGAAAGCATGA
	R	AGTAGACAGAAGAGCGTGGT
Mmp8 (mouse)	F	Qiagen
	R	
Mmp9 (mouse)	F	Qiagen
	R	

604

605 **Lipocalin-2 ELISA**

606 Lipocalin-2 ELISA (R&D Systems) was performed to determine gut inflammation from fecal samples
 607 according to the manufacturer's instructions. Fecal pellets were suspended in sterile PBS (BioConcept),
 608 diluted 1:20, 1:400 or undiluted, and the concentrations were determined by curve fitting using Four-
 609 Parametric Logistic Regression.

610

611 **Immunofluorescence**

612 Cecal tissue sections from mice were carefully dissected, fixed with 4% paraformaldehyde, saturated in
 613 20% sucrose/PBS, and snap-frozen in Optimal Cutting Temperature compound (OCT, Tissue-Tek).
 614 Samples were stored in -80°C freezer until further analysis. Samples to be stained were cut in 10µm
 615 cross-sections and mounted on glass slides (Superfrost++, Thermo Scientific). For staining, cryosections
 616 on the glass slides were air-dried, rehydrated with PBS and permeabilized using a 0.5% TritonX-
 617 100/PBS solution. Sections were blocked using 10% Normal Goat Serum (NGS)/PBS before staining
 618 with primary and secondary antibodies. The following antibodies and dilutions were used for the
 619 staining of different samples: 1:200 EpCam/CD326 (clone G8.8, Biolegend), 1:200 α-S.Tm LPS (O-
 620 antigen group B factor 4-5, Difco), 1:200 α-Ki67 (ab15580, Abcam Biochemicals), or 1:200 α-Ly6B.2
 621 clone 7/4, BioRad) in combination with the respective secondary antibodies, i.e α-rabbit-AlexaFluor488
 622 (Abcam Biochemicals), α-rat-Cy3 (Jackson), fluorescent probes, i.e. CruzFluor488-conjugated
 623 Phalloidin (Santa Cruz Biotechnology), AlexaFluor647-conjugated Phalloidin (Molecular Probes),
 624 and/or DAPI (Sigma Aldrich). Stained sections were then covered with a glass slip using Mowiol (VWR
 625 International AG) and kept in dark at room temperature (RT) over night. For confocal microscopy

626 imaging, a Zeiss Axiovert 200m microscope with 10-100x objectives or a spinning disc confocal lased
627 unit (Visitron) with 10-100x objectives were used. Images were processed or analyzed with Visiview
628 (Visitron) and/or ImageJ. Manual quantification was done blindly on two different sections (3 to 5
629 regions per section) from the same mouse according to the indicated parameters. The number of
630 neutrophils per 63X field of view were counted on epithelium where half of the field included the lumen
631 close to the epithelium to include freshly transmigrated neutrophils. Average crypt sizes were
632 determined by counting the number of EpCAM positive cells per one crypt structure. Epithelial gaps
633 were defined as the mucosal regions where content of the lumen was in direct contact with the
634 lamina propria. The epithelium associated S.Tm cells were counted by scanning the area in 5-10 μ m
635 close proximity to epithelium on the luminal side.

636

637 **Statistical analysis**

638 Whenever applicable, the two-tailed Mann Whitney-U test was used to assess statistical significance
639 as indicated in the figure legends. GraphPad Prism 8 for Windows was used for statistical testing.

640 Evenness indices were calculated as previously described [12].

641

642 **References:**

- 643 1. Loetscher Y, Wieser A, Lengefeld J, Kaiser P, Schubert S, Heikenwalder M, et al. Salmonella
644 Transiently Reside in Luminal Neutrophils in the Inflamed Gut. *Plos One*. 2012;7(4). doi: ARTN e34812
645 10.1371/journal.pone.0034812. PubMed PMID: WOS:000305012700060.
- 646 2. Hapfelmeier S, Stecher B, Barthel M, Kremer M, Muller AJ, Heikenwalder M, et al. The
647 Salmonella pathogenicity island (SPI)-2 and SPI-1 type III secretion systems allow Salmonella serovar
648 typhimurium to trigger colitis via MyD88-dependent and MyD88-independent mechanisms. *J Immunol*.
649 2005;174(3):1675-85. PubMed PMID: 15661931.
- 650 3. Day DW, Mandal BK, Morson BC. The rectal biopsy appearances in Salmonella colitis.
651 *Histopathology*. 1978;2(2):117-31. doi: 10.1111/j.1365-2559.1978.tb01700.x. PubMed PMID: 669591.
- 652 4. Boyd JF. Pathology of the Alimentary-Tract in Salmonella-Typhimurium Food Poisoning. *Gut*.
653 1985;26(9):935-44. doi: DOI 10.1136/gut.26.9.935. PubMed PMID: WOS:A1985APV5800011.
- 654 5. Wera O, Lancellotti P, Oury C. The Dual Role of Neutrophils in Inflammatory Bowel Diseases.
655 *J Clin Med*. 2016;5(12). doi: ARTN 118
656 10.3390/jcm5120118. PubMed PMID: WOS:000391050900012.
- 657 6. Campbell EL, Bruyninckx WJ, Kelly CJ, Glover LE, McNamee EN, Bowers BE, et al.
658 Transmigrating Neutrophils Shape the Mucosal Microenvironment through Localized Oxygen
659 Depletion to Influence Resolution of Inflammation. *Immunity*. 2014;40(1):66-77. doi:
660 10.1016/j.immuni.2013.11.020. PubMed PMID: WOS:000331476900010.
- 661 7. Rosales C. Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? *Front*
662 *Physiol*. 2018;9. doi: ARTN 113
663 10.3389/fphys.2018.00113. PubMed PMID: WOS:000425529100001.
- 664 8. Fournier BM, Parkos CA. The role of neutrophils during intestinal inflammation. *Mucosal*
665 *Immunol*. 2012;5(4):354-66. Epub 2012/04/12. doi: 10.1038/mi.2012.24. PubMed PMID: 22491176.
- 666 9. Stecher B, Robbiani R, Walker AW, Westendorf AM, Barthel M, Kremer M, et al. Salmonella
667 enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota. *PLoS*
668 *Biol*. 2007;5(10):2177-89. doi: 10.1371/journal.pbio.0050244. PubMed PMID: 17760501; PubMed
669 Central PMCID: PMC1951780.
- 670 10. Barthel M, Hapfelmeier S, Quintanilla-Martinez L, Kremer M, Rohde M, Hogardt M, et al.
671 Pretreatment of mice with streptomycin provides a Salmonella enterica serovar typhimurium colitis
672 model that allows analysis of both pathogen and host. *Infection and Immunity*. 2003;71(5):2839-58. doi:
673 10.1128/Iai.71.5.2839-2858.2003. PubMed PMID: WOS:000182501500061.
- 674 11. Muller AA, Dolowschiak T, Sellin ME, Felmy B, Verbree C, Gadiant S, et al. An NK Cell
675 Perforin Response Elicited via IL-18 Controls Mucosal Inflammation Kinetics during Salmonella Gut
676 Infection. *PLoS Pathog*. 2016;12(6):e1005723. Epub 2016/06/25. doi: 10.1371/journal.ppat.1005723.
677 PubMed PMID: 27341123; PubMed Central PMCID: PMC4920399.
- 678 12. Maier L, Diard M, Sellin ME, Chouffane ES, Trautwein-Weidner K, Periaswamy B, et al.
679 Granulocytes impose a tight bottleneck upon the gut luminal pathogen population during Salmonella
680 typhimurium colitis. *PLoS Pathog*. 2014;10(12):e1004557. doi: 10.1371/journal.ppat.1004557. PubMed
681 PMID: 25522364; PubMed Central PMCID: PMC4270771.
- 682 13. Sellin ME, Muller AA, Felmy B, Dolowschiak T, Diard M, Tardivel A, et al. Epithelium-
683 intrinsic NAIP/NLRC4 inflammasome drives infected enterocyte expulsion to restrict Salmonella
684 replication in the intestinal mucosa. *Cell host & microbe*. 2014;16(2):237-48. doi:
685 10.1016/j.chom.2014.07.001. PubMed PMID: 25121751.
- 686 14. Hausmann A, Bock D, Geiser P, Berthold DL, Fattinger SA, Furter M, et al. Intestinal epithelial
687 NAIP/NLRC4 restricts systemic dissemination of the adapted pathogen Salmonella Typhimurium due

- 688 to site-specific bacterial PAMP expression. *Mucosal Immunol.* 2020;13(3):530-44. doi:
689 10.1038/s41385-019-0247-0. PubMed PMID: 31953493; PubMed Central PMCID: PMC7181392.
- 690 15. Fattinger SA, Sellin ME, Hardt WD. Epithelial inflammasomes in the defense against
691 *Salmonella* gut infection. *Current opinion in microbiology.* 2021;59:86-94. Epub 2020/11/01. doi:
692 10.1016/j.mib.2020.09.014. PubMed PMID: 33128958.
- 693 16. Laughlin RC, Knodler LA, Barhoumi R, Payne HR, Wu J, Gomez G, et al. Spatial Segregation
694 of Virulence Gene Expression during Acute Enteric Infection with *Salmonella enterica* serovar
695 Typhimurium. *mBio.* 2014;5(1). doi: ARTN e00946-13
696 10.1128/mBio.00946-13. PubMed PMID: WOS:000332526500031.
- 697 17. Knodler LA, Vallance BA, Celli J, Winfree S, Hansen B, Montero M, et al. Dissemination of
698 invasive *Salmonella* via bacterial-induced extrusion of mucosal epithelia. *P Natl Acad Sci USA.*
699 2010;107(41):17733-8. doi: 10.1073/pnas.1006098107. PubMed PMID: WOS:000282809700053.
- 700 18. Stecher B, Macpherson AJ, Hapfelmeier S, Kremer M, Stallmach T, Hardt WD. Comparison of
701 *Salmonella enterica* serovar Typhimurium colitis in germfree mice and mice pretreated with
702 streptomycin. *Infect Immun.* 2005;73(6):3228-41. doi: 10.1128/IAI.73.6.3228-3241.2005. PubMed
703 PMID: 15908347; PubMed Central PMCID: PMC1111827.
- 704 19. Broz P, Pelegrin P, Shao F. The gasdermins, a protein family executing cell death and
705 inflammation. *Nature Reviews Immunology.* 2020;20(3):143-57. doi: 10.1038/s41577-019-0228-2.
706 PubMed PMID: WOS:000519447500001.
- 707 20. Fattinger SA, Maurer L, Geiser P, Enz U, Ganguillet S, Gül E, et al. Gasdermin D is the only
708 Gasdermin that provides non-redundant protection against acute *Salmonella* gut infection.
709 bioRxiv. 2022:2022.11.24.517575. doi: 10.1101/2022.11.24.517575.
- 710 21. Fattinger SA, Geiser P, Ventayol PS, Di Martino ML, Furter M, Felmy B, et al. Epithelium-
711 autonomous NAIP/NLRC4 prevents TNF-driven inflammatory destruction of the gut epithelial barrier
712 in *Salmonella*-infected mice. *Mucosal Immunology.* 2021;14(3):615-29. doi: 10.1038/s41385-021-
713 00381-y. PubMed PMID: WOS:000629871400003.
- 714 22. Rauch I, Deets KA, Ji DX, von Moltke J, Tenthorey JL, Lee AY, et al. NAIP-NLRC4
715 Inflammasomes Coordinate Intestinal Epithelial Cell Expulsion with Eicosanoid and IL-18 Release via
716 Activation of Caspase-1 and-8. *Immunity.* 2017;46(4):649-59. doi: 10.1016/j.immuni.2017.03.016.
717 PubMed PMID: WOS:000399451100017.
- 718 23. Kaiser P, Slack E, Grant AJ, Hardt WD, Regoes RR. Lymph node colonization dynamics after
719 oral *Salmonella Typhimurium* infection in mice. *PLoS Pathog.* 2013;9(9):e1003532. doi:
720 10.1371/journal.ppat.1003532. PubMed PMID: 24068916; PubMed Central PMCID:
721 PMC3777876.
- 722 24. Grant AJ, Restif O, McKinley TJ, Sheppard M, Maskell DJ, Mastroeni P. Modelling within-
723 host spatiotemporal dynamics of invasive bacterial disease. *PLoS Biol.* 2008;6(4):e74. doi:
724 10.1371/journal.pbio.0060074. PubMed PMID: 18399718; PubMed Central PMCID: PMC2288627.
- 725 25. Molloy MJ, Grainger JR, Bouladoux N, Hand TW, Koo LY, Naik S, et al. Intraluminal
726 Containment of Commensal Outgrowth in the Gut during Infection-Induced Dysbiosis. *Cell host &*
727 *microbe.* 2013;14(3):318-28. doi: 10.1016/j.chom.2013.08.003. PubMed PMID:
728 WOS:000330852000011.
- 729 26. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil
730 extracellular traps kill bacteria. *Science.* 2004;303(5663):1532-5. doi: DOI 10.1126/science.1092385.
731 PubMed PMID: WOS:000220000100047.
- 732 27. Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. *Nature Reviews*
733 *Immunology.* 2018;18(2):134-47. doi: 10.1038/nri.2017.105. PubMed PMID: WOS:000423548800014.

- 734 28. Gul E, Sayar EH, Gungor B, Eroglu FK, Surucu N, Keles S, et al. Type I IFN-related NETosis
735 in ataxia telangiectasia and Artemis deficiency. *J Allergy Clin Immunol*. 2018;142(1):246-57. doi:
736 10.1016/j.jaci.2017.10.030. PubMed PMID: WOS:000437837500027.
- 737 29. Wigerblad G, Kaplan MJ. Neutrophil extracellular traps in systemic autoimmune and
738 autoinflammatory diseases. *Nature Reviews Immunology*. 2022. doi: 10.1038/s41577-022-00787-0.
739 PubMed PMID: WOS:000869593900001.
- 740 30. Saha P, San Yeoh B, Xiao X, Golonka RM, Singh V, Wang YM, et al. PAD4-dependent NETs
741 generation are indispensable for intestinal clearance of *Citrobacter rodentium*. *Mucosal Immunology*.
742 2019;12(3):761-71. doi: 10.1038/s41385-019-0139-3. PubMed PMID: WOS:000464498600017.
- 743 31. Lewis HD, Liddle J, Coote JE, Atkinson SJ, Barker MD, Bax BD, et al. Inhibition of PAD4
744 activity is sufficient to disrupt mouse and human NET formation. *Nature Chemical Biology*.
745 2015;11(3):189-+. doi: 10.1038/nchembio.1735. PubMed PMID: WOS:000349840500006.
- 746 32. Xia X, Zhang ZZ, Zhu CC, Ni B, Wang SC, Yang SF, et al. Neutrophil extracellular traps
747 promote metastasis in gastric cancer patients with postoperative abdominal infectious complications.
748 *Nature Communications*. 2022;13(1). doi: ARTN 1017
749 10.1038/s41467-022-28492-5. PubMed PMID: WOS:000760426000020.
- 750 33. Guiducci E, Lemberg C, Kung N, Schraner E, Theocharides APA, LeibundGut-Landmann S.
751 *Candida albicans*-Induced NETosis Is Independent of Peptidylarginine Deiminase 4. *Frontiers in*
752 *immunology*. 2018;9. doi: ARTN 1573
753 10.3389/fimmu.2018.01573. PubMed PMID: WOS:000437881000001.
- 754 34. Herp S, Brugiroux S, Garzetti D, Ring D, Jochum LM, Beutler M, et al. *Mucispirillum*
755 *schaedleri* Antagonizes *Salmonella* Virulence to Protect Mice against Colitis. *Cell host & microbe*.
756 2019;25(5):681-+. doi: 10.1016/j.chom.2019.03.004. PubMed PMID: WOS:000467222600009.
- 757 35. Kreuzer M, Hardt WD. How Food Affects Colonization Resistance Against Enteropathogenic
758 Bacteria. *Annual Review of Microbiology*, Vol 74, 2020. 2020;74:787-813. doi: 10.1146/annurev-
759 micro-020420-013457. PubMed PMID: WOS:000613937400037.
- 760 36. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue
761 remodelling. *Nat Rev Mol Cell Bio*. 2007;8(3):221-33. doi: 10.1038/nrm2125. PubMed PMID:
762 WOS:000244479900017.
- 763 37. Fierer J. Invasive Non-typhoidal *Salmonella* (iNTS) Infections. *Clinical Infectious Diseases*.
764 2022;75(4):732-8. doi: 10.1093/cid/ciac035. PubMed PMID: WOS:000788254600001.
- 765 38. McDermott AJ, Huffnagle GB. The microbiome and regulation of mucosal immunity.
766 *Immunology*. 2014;142(1):24-31. doi: 10.1111/imm.12231. PubMed PMID: WOS:000333990100002.
- 767 39. Wotzka SY, Kreuzer M, Maier L, Arnoldini M, Nguyen BD, Brachmann AO, et al. *Escherichia*
768 *coli* limits *Salmonella* Typhimurium infections after diet shifts and fat-mediated microbiota perturbation
769 in mice. *Nature Microbiology*. 2019;4(12):2164-74. doi: 10.1038/s41564-019-0568-5. PubMed PMID:
770 WOS:000499071100020.
- 771 40. Brugiroux S, Beutler M, Pfann C, Garzetti D, Ruscheweyh HJ, Ring D, et al. Genome-guided
772 design of a defined mouse microbiota that confers colonization resistance against *Salmonella enterica*
773 serovar Typhimurium. *Nature Microbiology*. 2017;2(2). doi: ARTN 16215
774 10.1038/nmicrobiol.2016.215. PubMed PMID: WOS:000397104900013.
- 775 41. Furter M, Sellin ME, Hansson GC, Hardt WD. Mucus Architecture and Near-Surface
776 Swimming Affect Distinct *Salmonella* Typhimurium Infection Patterns along the Murine Intestinal
777 Tract. *Cell Rep*. 2019;27(9):2665-78 e3. doi: 10.1016/j.celrep.2019.04.106. PubMed PMID: 31141690;
778 PubMed Central PMCID: PMC6547020.

- 779 42. Stecher B, Barthel M, Schlumberger MC, Haberli L, Rabsch W, Kremer M, et al. Motility allows
780 *S. Typhimurium* to benefit from the mucosal defence. *Cellular microbiology*. 2008;10(5):1166-80. doi:
781 10.1111/j.1462-5822.2008.01118.x. PubMed PMID: 18241212.
- 782 43. Hoiseth SK, Stocker BA. Aromatic-dependent *Salmonella typhimurium* are non-virulent and
783 effective as live vaccines. *Nature*. 1981;291(5812):238-9. PubMed PMID: 7015147.
- 784 44. Periaswamy B, Maier L, Vishwakarma V, Slack E, Kremer M, Andrews-Polymenis HL, et al.
785 Live attenuated *S. Typhimurium* vaccine with improved safety in immuno-compromised mice. *PLoS*
786 *One*. 2012;7(9):e45433. Epub 2012/10/03. doi: 10.1371/journal.pone.0045433. PubMed PMID:
787 23029007; PubMed Central PMCID: PMC3454430.
- 788 45. Maier L, Vyas R, Cordova CD, Lindsay H, Schmidt TS, Brugiroux S, et al. Microbiota-derived
789 hydrogen fuels *Salmonella typhimurium* invasion of the gut ecosystem. *Cell host & microbe*.
790 2013;14(6):641-51. doi: 10.1016/j.chom.2013.11.002. PubMed PMID: 24331462.

791